16 results about "Cardiac ischemia" patented technology

Systems and Methods are disclosed for detecting acute coronary syndrome (ACS) events, arrythmias, heart rate abnormalities, medication problems such as non-compliance or ineffective amount or type of medication, and demand / supply related cardiac ischemia. The system may have both implanted and external components that communicate with a Physicians's programmer, and smart-devices for monitoring and alerting to detected medically relevant events or states. At least one processor provides event detection using statistical threshold criteria calculated upon at least a portion of a patient's data / distributions and set for a patient or based upon what a doctor determines as abnormal for a patient. Cardiovascular condition is tracked using histogram, trend, and summary information related to heart rate and / or cardiac features such as S-T segment measures of heartbeats. Heartbeats with elevated rates, and below a “high” range, provide medically relevant detections including medication non-compliance. Novel methods of power management and patient monitoring are disclosed.

This invention discloses an intestinal fungus Saccharomyces cerevisiae M7015 and its applications belong to the field of microbial technology. Saccharomyces cerevisiae The accession number for M7015 is GDMCC No. 66195. This invention first demonstrated, using a mouse subcutaneous stroma embolism model, that the aforementioned strain can promote angiogenesis; secondly, using mouse and Bama miniature pig myocardial infarction models, it was found that the aforementioned strain can promote collateral angiogenesis in ischemic areas of the heart and improve cardiac function. This invention not only fully elucidates... Saccharomyces cerevisiae M7015 promotes the formation of collateral vessels in the heart and improves cardiac function, and also reveals the broad application prospects of this bacterium in the treatment of vascular diseases.

The present application relates to a death receptor 5 (DR5) domain variant. The present application further relates to a fusion protein containing the DR5 domain variant, which has one or more of the following properties: (1) the ability to bind to TRAIL, (2) blocking apoptosis induced by the TRAIL / DR5 pathway, (3) reducing the size of myocardial infarction in cardiac ischemia and / or ischemia-reperfusion, and (4) having a protective effect against cerebral infarction. The present application further provides a method for producing the fusion protein and uses thereof.

Provided herein are methods for mitigating heart injury and improving cardiac function in a subject after a cardiac event, for example, an ischemic myocardial infarction (also called acute coronary syndrome). A Toll-like receptor 7 / 8 antagonist, such as Enpatoran, or an Itgam neutralizing antibody, administered to the subject before, during, or shortly after cardiac ischemia, offers a strong therapeutic protection with a significant reduction in myocardial infarction size or marked improved cardiac function.

The application discloses an application of curcumin polyethylene glycol polysulfide propylene micelles in treating cardiac reperfusion injury, especially in treating cardiac reperfusion injury drugs. The application proves that the curcumin polyethylene glycol polysulfide propylene micelles have great potential as a cardiac ischemia-reperfusion injury treatment drug, first discloses that the curcumin polyethylene glycol polysulfide propylene micelles have good protection effect on cardiac ischemia-reperfusion, provides an effective new potential alternative drug for clinical prevention and treatment of cardiac reperfusion injury, expands the indications of the curcumin polyethylene glycol polysulfide propylene micelles, and greatly improves the application potential and market prospect of the curcumin polyethylene glycol polysulfide propylene micelles.

The present application relates to a death receptor 5 (DR5) domain variant. The invention also relates to a fusion protein containing the DR5 structural domain variant. The fusion protein has one or more of the following properties: (1) the fusion protein can be combined with TRAIL; (2) blocking cell apoptosis induced by a TRAIL / DR5 pathway; (3) reducing the area of myocardial infarction in cardiac ischemia and / or ischemia-reperfusion; and (4) the pharmaceutical composition has a protective effect on cerebral infarction. The invention also provides a preparation method and application of the fusion protein.

The application discloses application of Piancizhu in preparation of a medicine for preventing and / or treating myocardial infarction. The application first discovers that Piancizhu can play an anti-cardiac ischemic injury role by improving heart function of a mouse model of left anterior descending branch stenosis of coronary artery, inhibiting inflammation levels of a heart, peripheral blood and bone marrow after cardiac infarction, reducing a myocardial infarction area and improving cardiac function disorder. Therefore, the application provides a scientific basis for increasing a clinical treatment indication of Piancizhu in acute myocardial infarction, simultaneously provides a new drug selection for clinical treatment of an acute cardiac infarction patient due to a good anti-inflammatory effect, and has a good application prospect.

A system for virtual cardiac ischemia imaging comprises a positioning device, a probe sensor device, a lead electrode sensor device, an analysis device, and a display device. Through the system for virtual cardiac ischemia imaging, lead electrodes is precisely attached on body surface of torso of a subject in need thereof, ischemic condition of heart of the subject is precisely simulated and does not require utilization of nuclear medicine examination to estimate shape of the heart of the subject. A method for virtual cardiac ischemia imaging is realized through the components of the system for virtual cardiac ischemia imaging.

The present application relates to a nucleic acid molecule comprising a first nucleic acid sequence comprising at least a portion of a 5′ untranslated region (5′ UTR) of a carboxylesterase gene and a second nucleic acid sequence encoding a protein of interest, where the second nucleic acid sequence is heterologous to and operatively coupled to the first nucleic acid sequence. Also disclosed are methods of expressing a protein of interest in a target cell, methods of treating subject for cardiac ischemia or hepatic ischemia, and methods of identifying a nucleic acid sequence capable of selectively enhancing translation of a heterologous protein of interest in a target cell.

Disclosed are analogs of elamipretide (MTP-131). The compounds are useful for the treatment and prevention of ischemia-reperfusion injury (e.g., cardiac ischemia-reperfusion injury) or myocardial infarction.

The invention belongs to the field of gene drugs, and particularly relates to an OSGIN2 gene and application of an adenovirus of the OSGIN2 gene. The nucleotide sequence of the OSGIN2 gene is shown as SEQ ID NO.1. When ischemia reperfusion injury occurs, the expression activity of the OSGIN2 gene is remarkably reduced, and the OSGIN2 gene is highly related to myocardial cell ferroptosis; and overexpression of the OSGIN2 can significantly inhibit the myocardial infarction area. The invention provides application of an OSGIN2 gene as a biomarker according to a myocardial cell death regulation mechanism of the OSGIN2 gene, and provides a product for detecting myocardial cell ferroptosis or cardiac ischemia-reperfusion injury. The overexpression virus of the OSGIN2 gene is constructed by relying on adenovirus, is conveyed to the position of a heart disease focus and can be used as a medicine for treating myocardial ischemia reperfusion, effective treatment of the focus is realized, and a medicine for preventing and / or treating the heart disease is provided.

The application discloses application of a CIP inhibitor in preparation of a medicine for treating myocardial infarction, and the application comprises the following steps: using a reagent for inhibiting CIP gene and / or CIP protein expression in preparation of a medicine for treating myocardial infarction, treating cardiac ischemia-reperfusion injury, reducing oxidative stress injury of myocardial cells, and reducing myocardial cell apoptosis. The application proves for the first time that inhibiting CIP protein can alleviate myocardial injury in a myocardial infarction process, reduce oxidative stress and myocardial cell apoptosis, and promote myocardial cell proliferation, and has great significance for treating ischemia-reperfusion injury caused by myocardial infarction, and provides a new technical selection for clinical treatment of myocardial infarction.

Disclosed are analogs of SBT-20. The compounds are useful for the treatment and prevention of ischemia-reperfusion injury (e.g., cardiac ischemia-reperfusion injury) or myocardial infarction.

A cardiac-targeting extracellular vesicle (EV), an EV for treating cardiovascular disease, and method of preparation and use thereof are provided. The EV contains a fusion sequence of Lamp-2b and peptide targeting cardiacmyocytes, CMP. It has been discovered that the cardiac-targeting EV exhibits the ability to specifically target the heart, thereby serving as a novel delivery tool system for cardiac-targeting therapy. The cardiac-targeting EV is loaded with miR-30d to obtain an EV for treating the cardiovascular disease, which demonstrates significant therapeutic effects on conditions such as cardiac ischemia-reperfusion injury and myocardial hypertrophy. This provides a new therapeutic approach for the clinical treatment of cardiovascular diseases. Additionally, targeted delivery of therapeutic agents using the cardiac-targeting EV is achieved, enabling effective prevention and treatment of cardiac diseases.

A use of regadenoson in the preparation of a drug for detecting a cardiac ischemic disease in echocardiography. The echocardiography is selected from one or more of stress echocardiography, myocardial contrast echocardiography, transthoracic Doppler echocardiography, and two-dimensional speckle tracking echocardiography. The cardiac ischemic disease is selected from one or more of a non-obstructive cardiac ischemic disease or an obstructive cardiac ischemic disease. By administering the drug, diagnosis of the disease in a patient exhibits good accuracy, sensitivity, specificity, and safety.

The present invention relates to pharmaceutical compositions for oral administration of A3R agonist compounds. The compositions are designed to disintegrate or disperse rapidly to deliver an effective dose of the compound for treating, ameliorating, or promoting recovery from certain conditions of the brain, central nervous system (CNS), or cardiovascular system such as a brain injury, a neurodegenerative condition, or cardiac ischemia.